Lazertinib
Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer[1].
Product Specifications
CAS Number
[1903008-80-9]
Product Name Alternative
YH25448; GNS-1480
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Lazertinib.html
Purity
99.87
Solubility
DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Molecular Formula
C30H34N8O3
Molecular Weight
554.64
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
EGFR/ErbB1/HER1
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
